StreetInsider.com News Articles

Ironwood Pharmaceuticals stock falls on CEO transition news

Fri, 16 Oct 2026 11:47:01 -0400

Investing.com --Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) shares fell 3.7% Friday following the company's announcement that Chief Commercial Officer Tammi Gaskins will replace Tom McCourt as Chief Executive Officer, effective January 1, 2027.

McCourt will retire from his CEO position after 17 years with the company, though he will remain on the Board of Directors. The leadership transition comes as Ironwood works to maintain momentum with its blockbuster drug LINZESS and advance its late-stage pipeline.

Gaskins joined Ironwood in 2020 and has served as Chief Commercial Officer, playing a role in establishing LINZESS as the number one prescribed brand in the U.S. for treating

Ironwood Pharmaceuticals stock falls on CEO transition news

Fri, 16 Oct 2026 11:47:01 -0400

Gaskins joined Ironwood in 2020 and has served as Chief Commercial Officer, playing a role in establishing LINZESS as the number one prescribed brand in the U.S. for treating

Form 8-K IRONWOOD PHARMACEUTICALS For: Oct 12

Fri, 16 Oct 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20261016/27195708.html

Ironwood Pharmaceuticals names Tammi Gaskins as next CEO

Fri, 16 Oct 2026 07:30:38 -0400

Ironwood Pharmaceuticals (Nasdaq: IRWD) announced that its board of directors has appointed Tammi Gaskins, currently chief commercial officer, as chief executive officer, effective January 1, 2027.

Current CEO Tom McCourt will retire from the role on that date but will remain a member of the board of directors. McCourt has been with the company for 17 years, serving as CEO since 2021.

Gaskins joined Ironwood in 2020 and has held leadership roles within the company's commercial organization. Before joining Ironwood, she held commercial leadership positions during a 20-year tenure at AstraZeneca.

"The Board of Directors selected Tammi Gaskins to be Ironwood's next CEO

Ironwood Pharmaceuticals names Tammi Gaskins as next CEO

Fri, 16 Oct 2026 07:30:38 -0400

Ironwood Pharmaceuticals (Nasdaq: IRWD) announced that its board of directors has appointed Tammi Gaskins, currently chief commercial officer, as chief executive officer, effective January 1, 2027.

Current CEO Tom McCourt will retire from the role on that date but will remain a member of the board of directors. McCourt has been with the company for 17 years, serving as CEO since 2021.

"The Board of Directors selected Tammi Gaskins to be Ironwood's next CEO

Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer

Fri, 16 Oct 2026 07:30:00 -0400

– Tom McCourt to Retire from CEO Post After 17 Years at Ironwood and Four Decades of Distinguished Industry Leadership Bringing Transformational Medicines to Patients –

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that its Board of Directors appointed Chief Commercial Officer Tammi Gaskins as Chief Executive Officer and a member of the Board of Directors, effective January 1, 2027. On that date Chief Executive Officer Tom McCourt will retire from his current role

Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer

Fri, 16 Oct 2026 07:30:00 -0400

– Tom McCourt to Retire from CEO Post After 17 Years at Ironwood and Four Decades of Distinguished Industry Leadership Bringing Transformational Medicines to Patients –

Form 144 IRONWOOD PHARMACEUTICALS Filed by: Shetzline Michael

Wed, 23 Sep 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260923/27096818.html

Form 4 IRONWOOD PHARMACEUTICALS For: Sep 15 Filed by: DENNER ALEXANDER J

Thu, 17 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260917/27075858.html

Form SCHEDULE 13G/A IRONWOOD PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:19:00 -0400

si-local-file:///var/storage/secattach/20260814/26926290.html

Form SCHEDULE 13G/A IRONWOOD PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:19:00 -0400

si-local-file:///var/storage/secattach/20260814/26926290.html

Form SCHEDULE 13G IRONWOOD PHARMACEUTICALS Filed by: STATE STREET CORP

Fri, 07 Aug 2026 09:58:00 -0400

si-local-file:///var/storage/secattach/20260807/26888743.html

Form SCHEDULE 13G IRONWOOD PHARMACEUTICALS Filed by: STATE STREET CORP

Fri, 07 Aug 2026 09:58:00 -0400

si-local-file:///var/storage/secattach/20260807/26888743.html

Form 10-Q IRONWOOD PHARMACEUTICALS For: Jun 30

Thu, 06 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26883803.html

Form 10-Q IRONWOOD PHARMACEUTICALS For: Jun 30

Thu, 06 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26883803.html

Form 8-K IRONWOOD PHARMACEUTICALS For: Aug 06

Thu, 06 Aug 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26878616.html

Form 8-K IRONWOOD PHARMACEUTICALS For: Aug 06

Thu, 06 Aug 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26878616.html

Ironwood Pharma (IRWD) Misses Q2 EPS by 7c

Thu, 06 Aug 2026 07:05:40 -0400

Ironwood Pharma (NASDAQ: IRWD) reported Q2 EPS of $0.31, $0.07 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $113.04 million versus the consensus estimate of $117.6 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Thu, 06 Aug 2026 07:05:00 -0400

– Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase year-over-year; Raises total revenue guidance to $460 - $485 million and adjusted EBITDA guidance to greater than $310 million –

– Q2 2026 LINZESS U.S. net sales of $282 million; $555 million year-to-date representing 44% year-over-year growth –

– Total revenue of $113 million, GAAP net income of $51 million and adjusted EBITDA of $83 million in Q2 2026; repaid $200 million convertible notes with cash on hand –

– Confirmatory Phase 3 STARS-2 trial of apraglutide in short

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Thu, 06 Aug 2026 07:05:00 -0400

– Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase year-over-year; Raises total revenue guidance to $460 - $485 million and adjusted EBITDA guidance to greater than $310 million –
– Q2 2026 LINZESS U.S. net sales of $282 million; $555 million year-to-date representing 44% year-over-year growth –
– Total revenue of $113 million, GAAP net income of $51 million and adjusted EBITDA of $83 million in Q2 2026; repaid $200 million convertible notes with cash on hand –
– Confirmatory Phase 3 STARS-2 trial of apraglutide in short

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Thu, 06 Aug 2026 07:05:00 -0400

– Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase year-over-year; Raises total revenue guidance to $460 - $485 million and adjusted EBITDA guidance to greater than $310 million –
– Q2 2026 LINZESS U.S. net sales of $282 million; $555 million year-to-date representing 44% year-over-year growth –
– Total revenue of $113 million, GAAP net income of $51 million and adjusted EBITDA of $83 million in Q2 2026; repaid $200 million convertible notes with cash on hand –
– Confirmatory Phase 3 STARS-2 trial of apraglutide in short

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Thu, 06 Aug 2026 07:05:00 -0400

– Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase year-over-year; Raises total revenue guidance to $460 - $485 million and adjusted EBITDA guidance to greater than $310 million –
– Q2 2026 LINZESS U.S. net sales of $282 million; $555 million year-to-date representing 44% year-over-year growth –
– Total revenue of $113 million, GAAP net income of $51 million and adjusted EBITDA of $83 million in Q2 2026; repaid $200 million convertible notes with cash on hand –
– Confirmatory Phase 3 STARS-2 trial of apraglutide in short

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Thu, 06 Aug 2026 07:05:00 -0400

– Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase year-over-year; Raises total revenue guidance to $460 - $485 million and adjusted EBITDA guidance to greater than $310 million –
– Q2 2026 LINZESS U.S. net sales of $282 million; $555 million year-to-date representing 44% year-over-year growth –
– Total revenue of $113 million, GAAP net income of $51 million and adjusted EBITDA of $83 million in Q2 2026; repaid $200 million convertible notes with cash on hand –
– Confirmatory Phase 3 STARS-2 trial of apraglutide in short

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Thu, 06 Aug 2026 07:05:00 -0400

– Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase year-over-year; Raises total revenue guidance to $460 - $485 million and adjusted EBITDA guidance to greater than $310 million –
– Q2 2026 LINZESS U.S. net sales of $282 million; $555 million year-to-date representing 44% year-over-year growth –
– Total revenue of $113 million, GAAP net income of $51 million and adjusted EBITDA of $83 million in Q2 2026; repaid $200 million convertible notes with cash on hand –
– Confirmatory Phase 3 STARS-2 trial of apraglutide in short

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Thu, 06 Aug 2026 07:05:00 -0400

– Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase year-over-year; Raises total revenue guidance to $460 - $485 million and adjusted EBITDA guidance to greater than $310 million –
– Q2 2026 LINZESS U.S. net sales of $282 million; $555 million year-to-date representing 44% year-over-year growth –
– Total revenue of $113 million, GAAP net income of $51 million and adjusted EBITDA of $83 million in Q2 2026; repaid $200 million convertible notes with cash on hand –
– Confirmatory Phase 3 STARS-2 trial of apraglutide in short